[go: up one dir, main page]

DE60011637D1 - Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen - Google Patents

Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen

Info

Publication number
DE60011637D1
DE60011637D1 DE60011637T DE60011637T DE60011637D1 DE 60011637 D1 DE60011637 D1 DE 60011637D1 DE 60011637 T DE60011637 T DE 60011637T DE 60011637 T DE60011637 T DE 60011637T DE 60011637 D1 DE60011637 D1 DE 60011637D1
Authority
DE
Germany
Prior art keywords
viral infections
prevention
treatment
nucleoside analogs
dioxolan nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011637T
Other languages
English (en)
Other versions
DE60011637T2 (de
Inventor
J Giles
Jean Bedard
Robert Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire BioChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire BioChem Inc filed Critical Shire BioChem Inc
Application granted granted Critical
Publication of DE60011637D1 publication Critical patent/DE60011637D1/de
Publication of DE60011637T2 publication Critical patent/DE60011637T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60011637T 1999-09-24 2000-09-22 Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen Expired - Lifetime DE60011637T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15570599P 1999-09-24 1999-09-24
US15570499P 1999-09-24 1999-09-24
US155705P 1999-09-24
US155704P 1999-09-24
PCT/CA2000/001094 WO2001022950A2 (en) 1999-09-24 2000-09-22 Diosolane nucleoside analogs for the treatment or prevention of viral infection

Publications (2)

Publication Number Publication Date
DE60011637D1 true DE60011637D1 (de) 2004-07-22
DE60011637T2 DE60011637T2 (de) 2004-11-11

Family

ID=26852544

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60011637T Expired - Lifetime DE60011637T2 (de) 1999-09-24 2000-09-22 Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen

Country Status (9)

Country Link
US (2) US6583149B1 (de)
EP (1) EP1214074B1 (de)
JP (1) JP2003510271A (de)
AT (1) ATE269081T1 (de)
AU (1) AU777869B2 (de)
CA (1) CA2385349A1 (de)
DE (1) DE60011637T2 (de)
ES (1) ES2218216T3 (de)
WO (1) WO2001022950A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5376950B2 (ja) * 2005-10-21 2013-12-25 エクセリクシス， インク． カゼインキナーゼｉｉ（ｃｋ２）モジュレーターとしてのピリミジオン類
US8171550B2 (en) * 2006-08-07 2012-05-01 Webroot Inc. System and method for defining and detecting pestware with function parameters
US8324231B2 (en) * 2007-04-25 2012-12-04 Exelixis, Inc. Pyrimidinones as casein kinase II (CK2) modulators
CN105055432A (zh) 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
BR112012002551A2 (pt) 2009-08-03 2017-06-13 Chimerix Inc composição e métodos de tratamento de infecções virais e tumores induzidos por vírus
DK2794624T3 (da) 2011-12-22 2019-07-22 Geron Corp Guanin-analoger som telomerase-substrater og påvirkere af telomer-længde
CN103288806A (zh) * 2013-07-02 2013-09-11 山东大学 一种曲沙他滨的合成方法
CN106138018B (zh) * 2015-04-02 2020-03-13 广州洁成生物科技有限公司 羟基二苯甲酮在制备抗病毒和抗肿瘤药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
ES2191013T3 (es) 1992-03-04 2003-09-01 Cell Therapeutics Inc Compuestos de xantina enantiomeros hidroxilados.
GB9226879D0 (en) 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
WO1995007086A1 (en) 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
SE506039C2 (sv) 1996-02-29 1997-11-03 Tetra Laval Holdings & Finance Homogeniseringsventil
US5792773A (en) 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792733A (en) 1997-08-14 1998-08-11 The Lubrizol Corporation Antiwear compositions containing phosphorus compounds and olefins
JP2002538780A (ja) 1999-02-11 2002-11-19 シェア バイオケム インコーポレーテッド ヌクレオシド類似体の立体選択的合成
CZ20013483A3 (cs) 1999-03-29 2002-04-17 Shire Biochem Inc. Pouľití sloučenin podle vynálezu pro přípravu farmaceutických přípravků k léčení leukémie
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use

Also Published As

Publication number Publication date
ATE269081T1 (de) 2004-07-15
JP2003510271A (ja) 2003-03-18
DE60011637T2 (de) 2004-11-11
WO2001022950A3 (en) 2001-10-25
WO2001022950A2 (en) 2001-04-05
AU7399000A (en) 2001-04-30
AU777869B2 (en) 2004-11-04
ES2218216T3 (es) 2004-11-16
EP1214074A2 (de) 2002-06-19
US6964968B2 (en) 2005-11-15
US6583149B1 (en) 2003-06-24
EP1214074B1 (de) 2004-06-16
US20040014757A1 (en) 2004-01-22
CA2385349A1 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
DK0666749T3 (da) Enantiomert rene beta-D-dioxalannukleosider med selektiv antihepatitis B virus aktivitet
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
WO2001060315A3 (en) Method for the treatment or prevention of flavivirus infections using nucleoside analogues
ATE512973T1 (de) Nukleosid-arylphosphoramidate und ihre verwendung als antivirale mittel zur behandlung von hepatitis-c-virus
MY136229A (en) Antiviral nucleoside derivatives
WO2001032153A3 (en) Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
PE20080179A1 (es) FORMAS CRISTALINAS DE LA SAL MALEATO DE 5-AMINO-3-(2',3'-DI-O-ACETIL-BETA-D-RIBOFURANOSIL)-3H-TIAZOLO[4,5-d]PIRIMIDIN-2-ONA
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
BR0008804A (pt) 4-oxo-4, 7-dihidrotieno [2,3-b] piridina-5-carboxamidas como agentes antivirais
EP0270317A3 (de) Pharmaceutische Zuberatung zur Behandlung von Virus-Krankheiten
WO2010068708A3 (en) 3'-azido purine nucleotide prodrugs for treatment of viral infections
DE60011637D1 (de) Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
DE60036862D1 (de) Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid-analoge
BR0107912A (pt) Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus
KR910000734A (ko) 네플라노신 유도체
DE69731483D1 (de) Beta-l-dioxolanuridin-analoge zur behandlung und vorbeugung von durch ebv, vzv bzw. hv-8 verursachten viralen infektionen
AU8441382A (en) Antiviral alpha alpha dialkyl adamantylethylamines
WO2004052905A3 (en) Antiviral nucleoside derivatives
WO2023154905A8 (en) Antiviral naphthyridinone compounds
KR960704464A (ko) 포유동물 세포에서의 뉴클레오사이드와 뉴클레오베이스 수송억제 방법 및 바이러스 복제억제 방법(method for inhibiting nucleoside and nucleoside transport and virus replication in mammalian cells)
BR9915993A (pt) Composto, composição farmacêutica, processo para inibir a replicação de um vìrus herpes, e, processo para tratar um paciente sofrendo de uma infecção de vìrus herpes
DE60022047D1 (de) Antivirale therapie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SHIRE CANADA INC., VILLE ST.-LAURENT, QUEBEC, CA